Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ZEPP vs OMCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMCL Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

OMCL Overall Winner 6-Pillar Tally: ZEPP 3 – 3 OMCL Matrix Metrics: ZEPP 4 – 6 OMCL

As of Nov 20, 2026, Omnicell Inc (OMCL) is the stronger overall head-to-head candidate over Zepp Health Corporation (ZEPP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ZEPP carries a Unified Composite Score of 45.7/100 (HOLD) at $2.31 (3.1x Forward P/E, -12.6% operating margin), whereas OMCL carries 45.2/100 (HOLD) at $32.51 (16.2x Forward P/E, 4.6% operating margin).

  • Technical & Structure Timing Caution: ZEPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.4); meanwhile OMCL is in a Breakdown options structure phase (RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZEPP vs OMCL
ZEPP NYSE
Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares
Electronic Computers
$2.31
-8.33% 1D
Market Cap $37.0M
TTM Revenue $276M
Forward P/E 3.1x
Beta / 30D Vol 2.12β · 68% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 63.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.0%), weak momentum, RSI 35
RSI-14: 35.4 · SMA20: $2.40 · SMA50: $3.21
OMCL NASDAQ Head-to-Head Winner
Omnicell Inc
Electronic Computers
$32.51
-2.02% 1D
Market Cap $1.5B
TTM Revenue $1.24B
Forward P/E 16.2x
Beta / 30D Vol 0.92β · 52% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 74.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.9 · SMA20: $35.92 · SMA50: $35.12

6-Pillar Scorecard Institutional Category Breakdown (ZEPP 3 – 3 OMCL)

Columns: Metric · ZEPP · OMCL
1. Valuation Multiples ZEPP
Forward P/E 3.1x 16.2x
Trailing P/E 3.1x 34.3x
PEG Ratio N/M 15.40x
EV / Revenue 0.1x 1.1x
2. Growth & Scale OMCL
Revenue Growth (YoY) +6.9% -0.9%
Earnings Growth (YoY) -68.1% +100.1%
TTM Revenue (USD) $276M $1.24B
Market Cap $37.0M $1.5B
3. Profitability & Quality OMCL
Gross Margin 38.6% 44.4%
Operating Margin -12.6% 4.6%
Net Profit Margin -15.8% 3.6%
Return on Equity (ROE) -21.2% 3.5%
4. Balance Sheet & Cash Flow OMCL
Cash Generation (TTM) -$30M EBITDA $133M
Cash Flow Margin -11.0% EBITDA Mgn 10.7%
Net Cash / Leverage $11.68 Book/Sh · -21.2% ROE $114M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZEPP
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 124.3% (94th %ile) 41.5% (21st %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat ZEPP
OpEx & R&D Intensity 51.2% of Rev ($141M) 39.8% of Rev ($495M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Consumer Electronics Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZEPP (4) vs OMCL (6)
Institutional Metric ZEPP OMCL Criterion Row Edge
Market Capitalization
Scale
$37.0M $1.5B Larger Scale OMCL
Trailing P/E Ratio
Valuation
3.1x 34.3x Lower Multiple ZEPP
Forward P/E Ratio
Valuation
3.1x 16.2x Lower Multiple ZEPP
Revenue Growth (YoY)
Growth
+6.9% -0.9% Higher Growth ZEPP
Operating Margin (TTM)
Profitability
-12.6% 4.6% Higher Margin OMCL
Net Profit Margin
Profitability
-15.8% 3.6% Higher Margin OMCL
Return on Equity (ROE)
Capital Efficiency
-21.2% 3.5% Higher ROE OMCL
52-Week Range Position
Momentum
0% ($2–$33) 3% ($32–$55) Stronger Trend OMCL
Beta / 30D Volatility
Risk Regime
2.12β · 68% Vol 0.92β · 52% Vol Lower Realized Risk OMCL
Unified Institutional Score
Composite Signal
45.7 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite ZEPP
Trailing 12M Revenue (USD)
Operating Scale
$276M $1.24B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
38.6% 44.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev 15.40x PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$30M EBITDA ($11.68 Book/Sh · -21.2% ROE) $133M ($114M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OMCL +0.79 pp
ZEPP: -13.16% · OMCL: -12.37%
3M Horizon OMCL +47.51 pp
ZEPP: -53.71% · OMCL: -6.2%
6M Horizon OMCL +46.4 pp
ZEPP: -73.2% · OMCL: -26.8%
1Y Horizon OMCL +84.54 pp
ZEPP: -90.39% · OMCL: -5.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZEPP vs OMCL. Trailing 12-month operating profitability (ZEPP -12.6% vs OMCL 4.6%) and valuation multiples (ZEPP 3.1x vs OMCL 16.2x Forward P/E) are benchmarked directly in Pillar 4 below.

ZEPP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$276M
Gross Margin38.6%
Op. Margin-12.6%
ROE / Fwd P/E-21.2% · 3.1x
OMCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.24B
Gross Margin44.4%
Op. Margin4.6%
ROE / Fwd P/E3.5% · 16.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZEPP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 124.3%
IV Percentile 94th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZEPP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OMCL BREAKDOWN
144d in phase · OBV DISTRIBUTION
Current IV 41.5%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZEPP Moat Profile Cyclical / Execution-Driven Positioning
Consumer Electronics Operator
Competes within the Consumer Electronics value chain with $37.0M market capitalization and -12.6% operating margin.
OpEx & R&D Reinvestment 51.2% of Rev ($141M)
90D Engineering Disclosures 0 Published
OMCL Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $1.5B market capitalization and 4.6% operating margin.
OpEx & R&D Reinvestment 39.8% of Rev ($495M)
90D Engineering Disclosures 0 Published

Investor FAQ ZEPP vs OMCL Key Questions & Quantitative Answers

As of Nov 20, 2026, Omnicell Inc (OMCL) is the stronger overall head-to-head candidate over Zepp Health Corporation (ZEPP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ZEPP carries a Unified Composite Score of 45.7/100 (HOLD) at $2.31 (3.1x Forward P/E, -12.6% operating margin), whereas OMCL carries 45.2/100 (HOLD) at $32.51 (16.2x Forward P/E, 4.6% operating margin). Technical & Structure Timing Caution: ZEPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.4); meanwhile OMCL is in a Breakdown options structure phase (RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OMCL leads the Growth & Scale pillar: ZEPP posts +6.9% YoY revenue growth and -68.1% YoY earnings growth on $276M TTM revenue (38.6% gross margin, -12.6% operating margin), compared with OMCL at -0.9% YoY revenue growth and +100.1% YoY earnings growth on $1.24B TTM revenue (44.4% gross margin, 4.6% operating margin). On trailing 12-month operating scale, ZEPP generates $276M in USD-normalized revenue versus $1.24B for OMCL. In operating R&D and SG&A reinvestment, ZEPP deploys 51.2% of Rev ($141M) (0 90-day corporate R&D disclosures) versus 39.8% of Rev ($495M) (0 disclosures) for OMCL.

ZEPP screens cheaper on headline valuation multiples. ZEPP trades at 3.1x Forward P/E, 3.1x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-11.0% EBITDA margin), whereas OMCL trades at 16.2x Forward P/E, 34.3x Trailing P/E, 15.40x PEG, and 1.1x EV/Revenue (10.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZEPP (-21.2% ROE) versus OMCL (3.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ZEPP carries 124.3% implied volatility (94th %ile, Extreme (>80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.12β · 68% Vol realized risk). By comparison, OMCL carries 41.5% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.92β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.